Related Experiment Video
Updated: Jun 28, 2026
07:54
Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis
Pranjal Rai1, Girish Bathla1, Niharika Praveen1
1Department of Radiology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN, 55902, USA.
Respiratory Medicine
|June 26, 2026
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1As) show promise in reducing cerebrovascular events and mortality in obstructive sleep apnea (OSA) patients. These findings suggest GLP-1As may be beneficial adjuncts to standard OSA care.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Sleep Medicine
Background:
- Obstructive sleep apnea (OSA) is linked to poor cerebrovascular outcomes.
- Glucagon-like peptide-1 receptor agonists (GLP-1As) have demonstrated cerebrovascular benefits in diabetes and obesity.
- Long-term GLP-1A effects in OSA patients remain unclear.
Purpose of the Study:
- To investigate the long-term impact of GLP-1A exposure on cerebrovascular events and mortality in adults with OSA.
- To assess the association between GLP-1A use and healthcare utilization in OSA patients.
Main Methods:
- Retrospective cohort study using the TriNetX US Collaborative Network (2016-2025).
- Identified adults with OSA and analyzed GLP-1A initiation.
- Utilized propensity score matching (1:1) and assessed outcomes at 1, 3, and 5 years.
Main Results:
- GLP-1A exposure was linked to significantly lower hazards of ischemic stroke, intracranial hemorrhage, and all-cause mortality.
- Reduced emergency department visits and inpatient hospitalizations were observed with GLP-1A use.
- Consistent associations were found in CPAP-restricted and tirzepatide-specific subgroup analyses.
Conclusions:
- GLP-1A exposure is associated with reduced cerebrovascular events, healthcare utilization, and mortality in a large OSA cohort.
- Findings are hypothesis-generating, suggesting potential benefits of incretin-based therapies in OSA management.
- Prospective studies are needed to validate these real-world observations.
Related Concept Videos
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:24Substance Use Disorders Affecting Sleep
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...